Annual report pursuant to Section 13 and 15(d)

Agreement with Sanofi-Aventis SA

v3.8.0.1
Agreement with Sanofi-Aventis SA
12 Months Ended
Dec. 31, 2017
Agreement [Abstract]  
Agreement [Text Block]
4. Agreement with Sanofi-Aventis SA
 
In 1997, we entered into an exclusive license agreement with Sanofi-Aventis. The agreement gave us a worldwide license to the patent rights and know-how related to the antipsychotic agent iloperidone, including the ability to develop, use, sublicense, manufacture and sell products and processes claimed in the patent rights. The license agreement provided that we pay royalties based on net sales. The underlying patent rights expired in November 2016.